BACKGROUND: The relationship between quality of life (QofL) and anemia has been the subject of recent debates; it has been suggested that the QofL changes associated with the treatment of anemia of chronic kidney disease (CKD) or ESRD patients should not be used in making decisions to treat anemia in CKD patients. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This study examines the relationship between Kidney Disease Quality of Life (KDQofL) questionnaire domains and hemoglobin (Hgb) levels in 1200 patients with stage 3, 4, and 5 CKD followed in seven centers. QofL measures were compared in a stepwise fashion for hemoglobin levels of <11, 11 to <12, 12 to <13, and > or =13. ANOVA was used to examine the relationship between QofL scores and Hgb level, age, CKD stage, and albumin level; a history of diabetes, congestive heart failure, or myocardial infarction; use of erythropoetic-stimulating agents (ESA); and the interaction of hemoglobin level and ESA. RESULTS: The results demonstrate that with increasing Hgb levels there is a statistically significant increase in all four physical domains, the energy/vitality domain, and the physical composite score of the SF-36, and the general health score on the kidney disease component of the questionnaire. The most dramatic improvements in these various domains occurred between the <11 and the 11 to 12 group. CONCLUSIONS: Higher Hgb levels are associated with improved QofL domains of the KDQofL questionnaire. These findings have implications for the care of CKD patients in terms of the initiation of and the Hgb target of ESA therapy.
BACKGROUND: The relationship between quality of life (QofL) and anemia has been the subject of recent debates; it has been suggested that the QofL changes associated with the treatment of anemia of chronic kidney disease (CKD) or ESRDpatients should not be used in making decisions to treat anemia in CKDpatients. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This study examines the relationship between Kidney Disease Quality of Life (KDQofL) questionnaire domains and hemoglobin (Hgb) levels in 1200 patients with stage 3, 4, and 5 CKD followed in seven centers. QofL measures were compared in a stepwise fashion for hemoglobin levels of <11, 11 to <12, 12 to <13, and > or =13. ANOVA was used to examine the relationship between QofL scores and Hgb level, age, CKD stage, and albumin level; a history of diabetes, congestive heart failure, or myocardial infarction; use of erythropoetic-stimulating agents (ESA); and the interaction of hemoglobin level and ESA. RESULTS: The results demonstrate that with increasing Hgb levels there is a statistically significant increase in all four physical domains, the energy/vitality domain, and the physical composite score of the SF-36, and the general health score on the kidney disease component of the questionnaire. The most dramatic improvements in these various domains occurred between the <11 and the 11 to 12 group. CONCLUSIONS: Higher Hgb levels are associated with improved QofL domains of the KDQofL questionnaire. These findings have implications for the care of CKDpatients in terms of the initiation of and the Hgb target of ESA therapy.
Authors: Patrick Lefebvre; Francis Vekeman; Brenda Sarokhan; Christopher Enny; Robert Provenzano; Pierre-Yves Cremieux Journal: Curr Med Res Opin Date: 2006-10 Impact factor: 2.580
Authors: Rachel L Perlman; Fredric O Finkelstein; Lei Liu; Erik Roys; Margaret Kiser; George Eisele; Sally Burrows-Hudson; Joseph M Messana; Nathan Levin; Sanjay Rajagopalan; Friedrich K Port; Robert A Wolfe; Rajiv Saran Journal: Am J Kidney Dis Date: 2005-04 Impact factor: 8.860
Authors: Antonio Alberto Lopes; Jennifer L Bragg-Gresham; David A Goodkin; Shunichi Fukuhara; Donna L Mapes; Eric W Young; Brenda W Gillespie; Tadao Akizawa; Roger N Greenwood; Vittorio E Andreucci; Takashi Akiba; Philip J Held; Friedrich K Port Journal: Qual Life Res Date: 2007-02-08 Impact factor: 4.147
Authors: Donna L Mapes; Antonio Alberto Lopes; Sudtida Satayathum; Keith P McCullough; David A Goodkin; Francesco Locatelli; Shunichi Fukuhara; Eric W Young; Kiyoshi Kurokawa; Akira Saito; Jürgen Bommer; Robert A Wolfe; Philip J Held; Friedrich K Port Journal: Kidney Int Date: 2003-07 Impact factor: 10.612
Authors: R Provenzano; L Garcia-Mayol; P Suchinda; B Von Hartitzsch; S B Woollen; R Zabaneh; J C Fink Journal: Clin Nephrol Date: 2004-06 Impact factor: 0.975
Authors: Fabiane Rossi dos Santos Grincenkov; Natália Fernandes; Alfredo Chaoubah; Neimar da Silva Fernandes; Kleyton Bastos; Antonio Alberto Lopes; Abdul Rashid Qureshi; Fredric O Finkelstein; Roberto Pecoits-Filho; José Carolino Divino-Filho; Marcus Gomes Bastos Journal: Perit Dial Int Date: 2013 Nov-Dec Impact factor: 1.756
Authors: Teresa K Chen; Michelle M Estrella; Brad C Astor; Tom Greene; Xuelei Wang; Morgan E Grams; Lawrence J Appel Journal: Nephrol Dial Transplant Date: 2015-03-27 Impact factor: 5.992
Authors: Daniel J Ryan; David Nei; Boone M Prentice; Kristie L Rose; Richard M Caprioli; Jeffrey M Spraggins Journal: Rapid Commun Mass Spectrom Date: 2018-03-15 Impact factor: 2.419
Authors: Simon D Roger; Sarbjit V Jassal; Michael C Woodward; Steven Soroka; Lawrence P McMahon Journal: Int Urol Nephrol Date: 2013-08-28 Impact factor: 2.370
Authors: Imran Memon; Keith C Norris; Andrew S Bomback; Carmen Peralta; Suying Li; Shu-Cheng Chen; Peter A McCullough; Adam Whaley-Connell; Claudine Jurkovitz; Manjula Kurella Tamura; Georges Saab Journal: Cardiorenal Med Date: 2013-06-01 Impact factor: 2.041